SOM Biotech

SOM Biotech is a drug innovation company based on a pioneering AI-based drug discovery technology – SOM AI PRO -, that has built a robust pipeline focused mainly on Orphan CNS products with very high unmet need and blockbuster potential. SOM AI PRO has been validated with 2 successful Phase 2 trials (TTR Amyloidosis, Chorea in Huntington disease), and four programs are at the preclinical stage. SOM Biotech applies the proprietary AI-based drug discovery technology for building its pipeline and strategic collaborations with the companies. The AI technology can be applied in any therapeutic area and allows advancing drug candidates into Phase 2a in less than one year (through 505b2 pathway). It also allows improving the effectiveness of drug discovery and drug life cycle management by the identification of novel targets and indications for the molecules.

SOM Biotech headquartered in Europe, operates in the Biotechnology, Artificial Intelligence (AI), Life Science, Health Care, Pharmaceutical, Medical sector. The company focuses on Biotechnology and has secured $959.1M in funding across 96 round(s). With a team of 11-50 employees, SOM Biotech is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - SOM Biotech, raised $2.2M. Discover more about their projects, partnerships, and impact on our platform.